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Introduction
Juvenile idiopathic arthritis (JIA) is a heterogenous dis-
ease, classified according to the International League of
Associations for Rheumatology (ILAR). Initial treatment
is based largely on disease severity; intra-articular injec-
tions for oligoarthritis, methotrexate (MTX) for polyar-
thritis and systemic presentations. The recent licensing
of biologic therapies for use in JIA has revolutionised
treatment of the disease. It is not currently known what
proportion of children who present with polyarthritis
will require biologic therapy. Although not studied for-
mally, it is recognised a proportion of children with oli-
goarthritis will also require systemic therapy to control
symptoms.
Objectives
To describe prescribing patterns in JIA over the first 3
years on presentation to rheumatology.
Methods
Children with at least 3 years of follow-up within the
Childhood Arthritis Prospective Study (CAPS), a pro-
spective observational inception study of inflammatory
arthritis, were included.
For analysis, children were placed into one of 4 groups
based on physician-assigned ILAR category and number of
active joints at first presentation (baseline): oligoarthritis,
polyarthritis, systemic (sJIA) and enthesitis-related arthritis
(ERA). All treatment exposures were categorised into
NSAID, intra-articular steroids, disease modifying anti-
rheumatic drug (DMARD) including MTX and sulphasa-
lazine (SSZ) and biologics including adalimumab (ADA),
etanercept (ETN), infliximab (INF), and tocilizumab
(TCZ).
Results
790 children were included originally (406 oligoarthritis,
221 polyarthritis, 42 sJIA and 43 ERA). Of these, 78 had
missing ILAR and were excluded, leaving 712 children.
Over a 3 year period, almost 100% of children with poly-
articular presentation and 50% with oligoarthritis went
on to receive a DMARD. 44% with polyarthritis and 17%
with oligoarticular presentation also received a biologic
(Table). The most recent ILAR category among children
with oligoarticular onset who received a biologic com-
prised 39% extended, 19% polyarthritis, 4% ERA, 11%
other subtypes; 27% had persistent oligoarthritis. All sJIA
patients were treated with DMARDs with 36% having
biologics . 63% of ERA patients receive a DMARD with
26% going on to receive a biologic. Table 1.
Conclusion
Over a three year period almost all patients with polyar-
thritis received treatment with MTX and almost 50% also
received a biologic therapy. A high proportion of children
presenting with oligoarthritis also went on to receive
DMARDs and biologics, many children for persistent oli-
goarthritis. This is despite the lack of clinical trial evidence1University of Manchester, Manchester,UK
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for effectiveness in this subtype. Further studies on the
efficacy/effectiveness in this subtype should be undertaken
to ensure appropriate use of advanced therapies in this
population.
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Table 1
Arthritis pattern at presentation N Ever had a DMARD, n(%) Ever had a biologic, n(%)
Oligoarthritis 406 204 (50) 70 (17)
Polyarthritis 221 217 (98) 98 (44)
Systemic arthritis 42 42 (100) 15 (36)
Enthesitis-related arthritis 43 27 (63) 11 (26)
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